Volume No. :   2

Issue No. :  4

Year :  2010

ISSN Print :  0975-234X

ISSN Online :  0975-4377


Allready Registrered
Click to Login

Design and Evaluation of Gatifloxacin Ocular Films for Sustained Release

Address:   Ajaykumar Patil1*, Raga Basawaraj, Md. Khaleed Ali, Anandkumar Joshi, Basawaraj Nanjwade2
1Dept. of Pharmaceutics, Karnataka College of Pharmacy, Manhalli Road, Bidar-585403, Karnataka, India.
2Dept. of Pharmaceutics, KLE Deemed University, Belgaum, Karnataka, India.
*Corresponding Author

Gatifloxacin ocular films were prepared by solvent casting method using hydroxy propyl methyl cellulose, methyl cellulose, sodium carboxy methyl cellulose and gelatin in different concentrations using glycerin as plasticizer. The physicochemical parameters of the ocular films were evaluated. The compatibility of the drug in the formulations was confirmed by IR studies. In vitro diffusion studies and mechanism of drug release was identified. The formulation F4 and F8 shows a maximum cumulative percentage drug release of 96.15 % and 97.34 % at the end of 12th h respectively. The drug release decreases in all the formulations as the concentration of polymer increases. The release of drug from the films has followed first-order kinetics and non-fickian in nature with diffusion controlled mechanism. The formulation F4 and F8 were subjected to UV-irradiation and in vivo drug release studies on rabbits. A high correlation coefficient was found between in vitro and in vivo release rate studies. No significant change in the drug content and physical features was observed during storage at 30±2°C/65±5% RH and 40±2°C/75±5% RH for three months. The data demonstrated that hydroxy propyl methyl cellulose and methyl cellulose in the concentration of 4.5% w/v was suitable for developing sustained release ocular films of gatifloxacin.
Gatifloxacin, Ocular films, HPMC, Sodium CMC, MC, Gelatin
Ajaykumar Patil1, Raga Basawaraj, Md. Khaleed Ali, Anandkumar Joshi, Basawaraj Nanjwade.Design and Evaluation of Gatifloxacin Ocular Films for Sustained Release. Research J. Pharma. Dosage Forms and Tech. 2010; 2(4): 277-280.
[View HTML]      [View PDF]

Visitor's No. :   194369